AI assistant
OptimizeRx Corp — Director's Dealing 2022
Feb 23, 2022
33090_dirs_2022-02-23_37f65a08-b13b-47e3-9cc4-96262a703bc7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-02-18
Reporting Person: FEBBO WILLIAM J (Director, CHIEF EXECUTIVE OFFICER)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-18 | Common Stock | S | 9200 | $43.379 | Disposed | 453138 | Direct |
| 2022-02-18 | Common Stock | S | 7066 | $44.122 | Disposed | 446072 | Direct |
| 2022-02-18 | Common Stock | S | 400 | $44.960 | Disposed | 445672 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.84 to $43.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.93 to $44.97. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.